Accelerated Bio and Pluristyx create Clinical Grade Induced Pluripotent Stem Cells from Reprogramming Human Trophoblast Stem Cells
2024年7月11日 - 9:36PM
ビジネスワイヤ(英語)
Accelerated Biosciences ("Accelerated Bio"), in partnership with
Pluristyx, proudly announces the successful creation of clinical
grade induced pluripotent stem cell (iPSC) lines using a novel
starting material.
This groundbreaking achievement utilizes Accelerated Bio’s
pre-implantation human trophoblast stem cells (hTSC) as the
foundational material. hTSCs are ethically sourced,
pre-implantation, low-passage (“young”) cells with unique
plasticity and high expansion capacity.
Starting with hTSCs, Pluristyx® reprogrammed two separate donor
stocks of GMP hTSCs with their proprietary mRNA reprogramming
technology to generate multiple iPSC clones for use as seed stock
for GMP master cell banks.
Benjamin Fryer, CEO of Pluristyx, expressed his enthusiasm about
the partnership: "Our partnership with Accelerated Bio aligns
perfectly with our mission to make iPSCs more accessible to the
industry. By leveraging our advanced reprogramming technology, we
aim to diversify the iPSC market, offering more choices for cell
therapy development."
Yuta Lee, CEO of Accelerated Bio, emphasized the advanced
capabilities of the hTSC platform: "Our hTSC platform is not only
the earliest ethically sourced pluripotent stem cell source but
also one of the most dynamic and versatile. This collaboration with
Pluristyx underscores the transformative potential of hTSCs in the
cell therapy industry."
Research-use-only counterparts of the clinical grade
hTSC-derived iPSC lines are available to test.
About Accelerated Biosciences
Accelerated Bio leads healthcare innovation by harnessing the
groundbreaking potential of hTSCs to revolutionize precision
medicine. Our hTSCs, originating from an early and ethical source,
excel in genetic stability, natural immune privilege, and high
expansion capacity. Our robust intellectual property portfolio
ensures the freedom to innovate, empowering both Accelerated Bio
and its partners. For more information, visit
www.acceleratedbio.com.
About Pluristyx
Pluristyx, through its panCELLa Platform, offers a portfolio of
unique iPSC-based technologies, proprietary genetic engineering,
and related tool-products and services to provide end-to-end client
support throughout the products’ lifecycle. Pluristyx is fast
becoming the leading provider of gene-edited iPSC and cell therapy
solutions, accelerating customers’ path to clinic, and providing
the best and fastest route to commercialization for cell-based
therapeutic products. For more information on Pluristyx, please
visit www.pluristyx.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240711430810/en/
Media: Angela Hu Accelerated Biosciences
angela.hu@acceleratedbio.com